Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE4

Conditions

HER2 + Breast Cancer · Advanced Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University People's Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (yuan peng) · 13671287670@163.com · 86+13671287670

Study leads

wang shu
Study Chair
Peking University People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Breast Cancer · Heart Failure

Abroad (travel likely)RecruitingPHASE2

Porto Alegre, Brazil · Porto Alegre, Brazil

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor

Abroad (travel likely)RecruitingPHASE3

Gilbert, United States · Beverly Hills, United States

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Zhengzhou, China